[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646102":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":48,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":20,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":78,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Medulloblastoma tissue collection and ex vivo translational research","EXPERIMENTAL","Participants with medulloblastoma undergoing standard-of-care surgical resection will be enrolled after informed consent. Tumor tissue collected during surgery will be used to generate patient-derived organoids (PDOs) for ex vivo translational research. Analyses will include molecular characterization, transcriptomic profiling, and evaluation of tumor cell responses to selected anticancer compounds in preclinical assays. No investigational drugs or medical devices are administered to participants, and no additional clinical procedures beyond routine care are performed.",[13],"Procedure: Tumor tissue collection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Tumor tissue collection","Tumor tissue will be collected during standard-of-care surgical resection of medulloblastoma. No additional surgical procedures will be performed for research purposes. Collected tissue will be used for molecular analyses and the establishment of patient-derived three-dimensional (3D) cultures for ex vivo translational research, including characterization of MYC-associated molecular pathways and evaluation of tumor cell responses to selected compounds in preclinical assays.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Gianpiero Tamburrini","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+393349468776","gianpiero.tamburrini@policlinicogemelli.it",[31],{"facility":32,"status":20,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Fondazione Policlinico Universitario \"A. Gemelli\", IRCCS - UOC Neurochirurgia Infantile","Rome","Lazio","00168","Italy","IT",{"type":39,"coordinates":40},"Point",[41,42],12.51133,41.89193,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":47,"phoneExt":20,"email":29},"GIANPIERO TAMBURRINI, MD","00393349468776",{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100646102","targeting-myc-in-high-risk-medulloblastoma-100646102",false,"NCT07694622","Targeting MYC in High-Risk Medulloblastoma","Exploiting High MYC Expression as a Potential Vulnerability for Treatment of High-Risk Medulloblastoma","MYCMB","Inclusion Criteria:\n\n* Patients with histologically confirmed Group 3 medulloblastoma (G3 MB)\n* Age between 0 and 20 years\n* Undergoing surgical treatment at the UOC Child Neurosurgery Unit, Fondazione Policlinico Universitario \"A. Gemelli\", IRCCS, Rome\n* Availability of tumor tissue obtained during standard-of-care surgical resection for molecular analyses and\u002For establishment of patient-derived organoids\n* Written informed consent provided by the patient and\u002For parent\u002Flegal guardian (prospective cohort)\n* Inclusion of retrospective cases in accordance with applicable Italian privacy regulations (Art. 110-bis)\n\nExclusion Criteria:\n\n* None","ALL","20 Years",{"count":61,"type":62},35,"ESTIMATED","INTERVENTIONAL",[65],"NA","Medulloblastoma is the most common malignant brain tumor in children. Group 3 medulloblastoma (G3 MB) represents the most aggressive molecular subtype and is associated with poor prognosis, particularly in cases characterized by high expression or amplification of the MYC oncogene. Current treatment strategies are not tailored to this subgroup and are associated with significant long-term toxicities, highlighting the need for more specific therapeutic approaches.\n\nThis study aims to characterize biological processes and molecular pathways driven by high MYC expression in high-risk G3 medulloblastoma in order to identify potential therapeutic vulnerabilities. The study will investigate MYC-associated regulation of gene expression and RNA splicing in tumor cells and will define molecular dependencies that may be targeted using candidate or repurposed anticancer agents.\n\nTo achieve this, publicly available genomic datasets will be analyzed, findings will be validated in patient tumor specimens, and patient-derived three-dimensional (3D) tumor models will be established from surgical samples. These models will be used for ex vivo assessment of selected therapeutic strategies in a system that preserves key features of the original tumor.\n\nThis translational approach integrates computational analyses, molecular validation, and functional testing in patient-derived models to improve understanding of MYC-associated tumor biology in Group 3 medulloblastoma.",[68],"Medulloblastoma",[68,70,71,72,73,74,75,76,77],"Group 3 Medulloblastoma","MYC","RNA Splicing","Patient-Derived 3D Cultures","Gene Expression","MYC Amplification","Organoids","Transcriptomics","NOT_YET_RECRUITING","2026-07-03",{"date":81,"type":82},"2026-07-10","ACTUAL",{"date":84,"type":62},"2026-09-01",{"date":86,"type":62},"2029-09-01",{"name":5,"class":6},1]